All In Biotech

Drug Trial Radar · NCT01490450

Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging, Multi-Center Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection in Adults With Active Psoriatic Arthritis

Last checked: Nov 20, 2026Latest source record: Nov 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 165 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

165

Actual

Start

Dec 2011

Primary completion

Jun 2013

Study completion Jun 2015

Sponsor

Lead sponsor
CSL BehringIndustry
Sponsor type
Industry
First posted
Dec 13, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to characterize the safety, efficacy and dose response of BMS-945429 in subjects with active Psoriatic Arthritis and an inadequate response to Nonsteroidal anti-inflammatory drugs (NSAIDs) and non-biologic Disease modifying anti-rheumatic drugs (DMARDs).

Conditions

  • Arthritis, Psoriatic

Interventions

  • Placebo matching BMS-945429Biological

    Injection, Subcutaneous, 0 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label

  • BMS-945429Biological

    Injection, Subcutaneous, 25 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label

  • BMS-945429Biological

    Injection, Subcutaneous, 100 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label

  • BMS-945429Biological

    Injection, Subcutaneous, 200 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent of Participants Achieving American College of Rheumatology Criteria 20% Response Rate (ACR20)Time frame: At 16 weeks

Locations

49 sites in 13 countries. Site status is shown where the registry gives one.

  • San Diego Arthritis Medical Clinic

    San Diego, California

  • Denver Arthritis Clinic

    Denver, Colorado

  • New England Research Associates, Llc

    Trumbull, Connecticut

  • Sarasota Arthritis Research Center

    Sarasota, Florida

  • Arthritis Associates Of Mississippi

    Jackson, Mississippi

  • Box Arthritis And Rheumatology Of The Carolinas, Pllc

    Charlotte, North Carolina

  • Health Research Of Oklahoma

    Oklahoma City, Oklahoma

  • East Penn Rheumatology Associates, P.C.

    Bethlehem, Pennsylvania

  • Local Institution

    San Miguel de Tucumán, Argentina

  • Local Institution

    Capital Federal, Buenos Aires, Argentina

  • Local Institution

    Capital Federal, Buenos Aires, Argentina

  • Local Institution

    Capital Federal, Buenos Aires, Argentina

  • Local Institution

    Cairns, Queensland, Australia

  • Local Institution

    Maroochydore, Queensland, Australia

  • Local Institution

    Woodville, South Australia, Australia

  • Local Institution

    Shenton Park, Western Australia, Australia

  • Manitoba Clinic

    Winnipeg, Manitoba, Canada

  • Local Institution

    Montreal, Quebec, Canada

  • Centre De Rhumatologie De L Est Du Quebec

    Rimouski, Quebec, Canada

  • Centre De Recherche Musculo-Squelettique

    Trois-Rivières, Quebec, Canada

  • Local Institution

    Pardubice, Czechia

  • Local Institution

    Prague, Czechia

  • Local Institution

    Bad Nauheim, Germany

  • Local Institution

    Erlangen, Germany

  • Local Institution

    Planegg, Germany

  • Local Institution

    Budapest, Hungary

  • Local Institution

    Budapest, Hungary

  • Local Institution

    Debrecen, Hungary

  • Local Institution

    Veszprém, Hungary

  • Local Institution

    Florence, Italy

  • Local Institution

    Naples, Italy

  • Local Institution

    México, Aguascalientes, Mexico

  • Local Institution

    Zapopan, Jalisco, Mexico

  • Local Institution

    Monterrey, Nuevo León, Mexico

  • Local Institution

    Bialystok, Poland

  • Local Institution

    Dąbrówka, Poland

  • Local Institution

    Elblag, Poland

  • Local Institution

    Poznan, Poland

  • Local Institution

    Warsaw, Poland

  • Local Institution

    Moscow, Russia

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.